



# VistaGen® Therapeutics

## COMPANY OVERVIEW

<https://ir.vistagen.com/tear-sheet>

## RECENT NEWS

**VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals for As-Needed Treatment of Social Anxiety Disorder**

Sep 13 2018, 8:30 AM EDT

**VistaGen Therapeutics Reports Fiscal 2019 First Quarter Financial Results**

Aug 14 2018, 4:49 PM EDT

**VistaGen Therapeutics and Baylor College of Medicine Collaborate on First-Step Study to Test VistaGen's AV-101 for Potential Anti-Suicidal Effects in Veterans**

Aug 13 2018, 8:30 AM EDT

## STOCK OVERVIEW

Symbol	VTGN
Exchange	Nasdaq
Market Cap	34.85m
Last Price	\$1.35
52-Week Range	\$0.69 - \$2.65

## INVESTOR RELATIONS

**VistaGen Therapeutics, Inc.**  
Mark A. McPartland  
Vice President, Corporate  
Development  
(650) 577-3606  
[markmcp@vistagen.com](mailto:markmcp@vistagen.com)  
KCSA Strategic Communications  
Valter Pinto / Allison Soss  
(212) 896-1254 / (212) 896-1267  
[VistaGen@KCSA.com](mailto:VistaGen@KCSA.com)

## MANAGEMENT TEAM

**Shawn K. Singh**  
Chief Executive Officer and Director

**H. Ralph Snodgrass, Ph.D.**  
Founder, President, Chief Scientific Officer  
and Director

**Mark A. Smith, M.D., Ph.D.**  
Chief Medical Officer

**Jerrold D. Dotson, CPA**  
Vice President, Chief Financial Officer and  
Secretary

**Mark A. McPartland**  
Vice President of Corporate Development

## VISTAGEN THERAPEUTICS, INC.

343 Allerton Avenue  
South San Francisco, CA 94080

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.